Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Bought by EFG Asset Management North America Corp.

EFG Asset Management North America Corp. grew its stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 99.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 74,190 shares of the biopharmaceutical company's stock after acquiring an additional 37,061 shares during the period. Intra-Cellular Therapies accounts for approximately 0.8% of EFG Asset Management North America Corp.'s portfolio, making the stock its 24th largest holding. EFG Asset Management North America Corp. owned 0.07% of Intra-Cellular Therapies worth $6,200,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of ITCI. Vanguard Group Inc. increased its holdings in Intra-Cellular Therapies by 1.0% in the 4th quarter. Vanguard Group Inc. now owns 9,721,360 shares of the biopharmaceutical company's stock worth $811,928,000 after buying an additional 93,107 shares in the last quarter. Wasatch Advisors LP grew its holdings in Intra-Cellular Therapies by 3.5% during the 3rd quarter. Wasatch Advisors LP now owns 3,848,588 shares of the biopharmaceutical company's stock valued at $281,601,000 after purchasing an additional 130,351 shares during the last quarter. Bellevue Group AG grew its position in Intra-Cellular Therapies by 0.6% in the 3rd quarter. Bellevue Group AG now owns 2,485,627 shares of the biopharmaceutical company's stock valued at $181,873,000 after acquiring an additional 14,342 shares during the last quarter. State Street Corp boosted its position in Intra-Cellular Therapies by 3.1% in the 3rd quarter. State Street Corp now owns 1,858,915 shares of the biopharmaceutical company's stock valued at $136,017,000 after buying an additional 56,664 shares during the period. Finally, Franklin Resources Inc. raised its position in Intra-Cellular Therapies by 9.7% during the 3rd quarter. Franklin Resources Inc. now owns 1,753,286 shares of the biopharmaceutical company's stock valued at $129,463,000 after purchasing an additional 155,655 shares in the last quarter. 92.33% of the stock is owned by institutional investors.

Remove Ads

Intra-Cellular Therapies Stock Up 0.0 %

Shares of ITCI traded up $0.06 on Friday, reaching $131.81. The stock had a trading volume of 1,584,630 shares, compared to its average volume of 1,391,525. The firm has a 50-day moving average of $129.12 and a 200 day moving average of $99.63. The firm has a market capitalization of $14.04 billion, a PE ratio of -151.50 and a beta of 0.69. Intra-Cellular Therapies, Inc. has a twelve month low of $64.09 and a twelve month high of $131.87.

Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last announced its quarterly earnings data on Friday, February 21st. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.08). The business had revenue of $199.22 million during the quarter, compared to analysts' expectations of $205.08 million. Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. On average, sell-side analysts anticipate that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on ITCI shares. Piper Sandler reaffirmed a "neutral" rating and set a $132.00 price objective (up previously from $107.00) on shares of Intra-Cellular Therapies in a research report on Tuesday, January 14th. Needham & Company LLC reaffirmed a "hold" rating on shares of Intra-Cellular Therapies in a report on Friday, February 21st. Canaccord Genuity Group lowered Intra-Cellular Therapies from a "buy" rating to a "hold" rating and raised their target price for the stock from $119.00 to $132.00 in a research note on Friday, January 31st. Baird R W cut Intra-Cellular Therapies from a "strong-buy" rating to a "hold" rating in a research note on Monday, January 13th. Finally, Royal Bank of Canada restated a "sector perform" rating and set a $132.00 price objective (up from $108.00) on shares of Intra-Cellular Therapies in a research note on Wednesday, January 22nd. Ten research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $106.08.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.